DOCSLIB.ORG

Product Sheet Info

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Product Sheet Info Product Information Sheet for NR-19546 Salmonella enterica subsp. enterica, Strain colder immediately upon arrival. For long-term storage, the ® vapor phase of a liquid nitrogen freezer is recommended. Ty2 (Serovar Typhi), Gateway Clone Set, Freeze-thaw cycles should be avoided. Recombinant in Escherichia coli, Plate 25 Growth Conditions: Catalog No. NR-19546 Media: This reagent is the tangible property of the U.S. Government. LB broth or agar containing 50 µg/mL kanamycin Incubation: For research use only. Not for human use. Temperature: E. coli, strain DH10B-T1 clones should be grown at 37°C. Contributor: Atmosphere: Aerobic Propagation: Pathogen Functional Genomics Resource Center at the J. 1. Scrape top of frozen well with a pipette tip and streak onto Craig Venter Institute agar plate. Manufacturer: 2. Incubate the plates at 37°C for 1 day. BEI Resources Citation: Product Description: Acknowledgment for publications should read “The following reagent was obtained through BEI Resources, NIAID, NIH: Production in the 96-well format has increased risk of cross- Salmonella enterica subsp. enterica, Strain Ty2 (Serovar contamination between adjacent wells. Individual clones Typhi), Gateway® Clone Set, Recombinant in Escherichia coli, should be purified (e.g. single colony isolation and purification Plate 25, NR-19546.” using good microbiological practices) and sequence-verified prior to use. BEI Resources does not confirm or validate Biosafety Level: 1 individual mutants provided by the contributor. Appropriate safety procedures should always be used with this The Salmonella enterica subsp. enterica (S. enterica subsp. material. Laboratory safety is discussed in the following enterica), strain Ty2 (serovar Typhi), Gateway® clone set publication: U.S. Department of Health and Human Services, consists of approximately 3380 sequence validated clones Public Health Service, Centers for Disease Control and from S. enterica subsp. enterica, strain Ty2, cloned in Prevention, and National Institutes of Health. Biosafety in Escherichia coli (E. coli) DH10B-T1 cells. Each open Microbiological and Biomedical Laboratories. 5th ed. reading frame was constructed in vector pDONR221 Washington, DC: U.S. Government Printing Office, 2009; see www.cdc.gov/biosafety/publications/bmbl5/index.htm. (Invitrogen) with an ATG start codon and no stop codon. The sequence was validated by full length sequencing of each Disclaimers: clone with greater than 1X coverage and a mutation rate of You are authorized to use this product for research use only. less than 0.2%. Detailed information about each clone is It is not intended for human use. shown in Table 1. Use of this product is subject to the terms and conditions of Information related to the use of Gateway® Clones can be the BEI Resources Material Transfer Agreement (MTA). The obtained from Invitrogen. Recombination was facilitated MTA is available on our Web site at www.beiresources.org. through an attB substrate (attB-PCR product or a linearized attB expression clone) with an attP substrate (pDONR221) While BEI Resources uses reasonable efforts to include to create an attL-containing entry clone. The entry clone accurate and up-to-date information on this product sheet, contains recombinational cloning sites, attL1 and attL2 to neither ATCC® nor the U.S. Government makes any facilitate gene transfer into a destination vector, M13 forward warranties or representations as to its accuracy. Citations and reverse priming sites for sequencing and a kanamycin from scientific literature and patents are provided for resistance gene for selection. Please refer to the Invitrogen informational purposes only. Neither ATCC® nor the U.S. ® Gateway Technology Manual for additional details. Government warrants that such information has been confirmed to be accurate. Plate orientation and viability were confirmed for NR-19546. This product is sent with the condition that you are responsible Material Provided: for its safe storage, handling, use and disposal. ATCC® and Each inoculated well of the 96-well plate contains the U.S. Government are not liable for any damages or injuries approximately 60 µL of E. coli culture (strain DH10B-T1) in arising from receipt and/or use of this product. While Luria Bertani (LB) broth containing 50 µg/mL kanamycin reasonable effort is made to ensure authenticity and reliability supplemented with 15% glycerol. of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for Packaging/Storage: damages arising from the misidentification or NR-19546 was packaged aseptically in a 96-well plate. The misrepresentation of products. product is provided frozen and should be stored at -80°C or BEI Resources E-mail: [email protected] www.beiresources.org Tel: 800-359-7370 Fax: 703-365-2898 © 2014/2019 American Type Culture Collection (ATCC). All rights reserved. NR-19546_04JAN2019 Page 1 of 3 Product Information Sheet for NR-19546 Use Restrictions: References: This material is distributed for internal research, non- 1. Deng, W., et al. “Comparative Genomics of Salmonella commercial purposes only. This material, its product or its enterica serovar Typhi strains Ty2 and CT18.” J. derivatives may not be distributed to third parties. Except as Bacteriol. 185 (2003): 2330-2337. PubMed: 12644504. performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or ATCC® is a trademark of the American Type Culture its derivatives must contact the contributor to determine if a Collection. license is required. U.S. Government contractors may need a license before first commercial sale. Table 1: Salmonella enterica subsp. enterica, Strain Ty2 (Serovar Typhi), Gateway® Clone Set, Recombinant in Escherichia coli, Plate 25 (ZSTDY)1 Average Clone Well ORF Accession Locus ID Description Depth of ID Position Length Number Coverage 93429 A01 t2216 2-keto-3-deoxygluconate permease 988 NP_805959.1 1.353239 93409 A02 t2846 hypothetical protein t2846 988 NP_806543.1 1.859312 93474 A03 t3333 trans-activator of MetE and MetH 988 NP_807001.1 1.947368 93449 A04 t3807 ADP-heptose:LPS heptosyl transferase I 988 NP_807429.1 1.902834 93285 A05 t0272 periplasmic negative regulator of SigmaE 991 NP_804148.1 1.468214 cytochrome o ubiquinol oxidase 93202 A06 t2417 991 NP_806147.1 1.965691 subunit II 93245 A07 t4186 cytochrome c-type biogenesis protein 991 NP_807790.1 1.859738 acetyl-CoA carboxylase carboxyltransferase subunit 93497 A08 t0233 994 NP_804114.1 1.808853 alpha 93263 A09 t1208 hypothetical protein t1208 994 NP_805015.1 1.783702 93229 A10 t1257 pathogenicity island protein 994 NP_805060.1 1.67002 93214 A11 t1732 23S rRNA pseudouridylate synthase C 994 NP_805507.1 1.968813 93186 A12 t2705 ribonucleotide-diphosphate reductase subunit beta 994 NP_806412.1 1.986922 93258 B01 t3545 regulatory protein 994 NP_807192.1 1.99497 93161 B02 t3667 phosphate transporter permease PstC 994 NP_807303.1 1.740443 93333 B03 t2077 hypothetical protein t2077 997 NP_805837.1 1.96991 93462 B04 t3488 biotin—protein ligase 997 NP_807140.1 1.82347 93397 B05 t3813 hypothetical protein t3813 997 NP_807435.1 1.521565 93353 B06 t0454 glucokinase 1000 NP_804317.1 1.788 93413 B07 t1585 mandelate racemase 1000 NP_805367.1 1.602 93169 B08 t2234 lipoyl synthase 1000 NP_805977.1 1.863 93349 B09 t3636 ribose ABC transporter permease 1000 NP_807273.1 1.633 93155 B10 t4453 hypothetical protein t4453 1000 NP_808040.1 1.778 93274 B11 t4569 hypothetical protein t4569 1000 NP_808147.1 1.846 93433 B12 t1186 succinylglutamate desuccinylase 1003 NP_804993.1 1.66999 93241 C01 t1286 type III secretion system protein 1003 NP_805089.1 1.912263 93146 C02 t2760 hydrogenase isoenzyme formation protein HypE 1003 NP_806461.2 1.983051 93253 C03 t3144 drug efflux protein 1003 NP_806825.1 1.579262 93193 C04 t4273 hypothetical protein t4273 1003 NP_807871.1 2.569292 93249 C05 t4400 phosphatidylserine decarboxylase 1003 NP_807991.1 1.814556 93297 C06 t0427 cysteine synthase A 1006 NP_804296.1 1.700795 93390 C07 t0971 hypothetical protein t0971 1006 NP_804794.1 1.754473 lipid A biosynthesis (KDO)2-(lauroyl)-lipid IVA 93309 C08 t0988 1006 NP_804811.1 1.225646 acyltransferase 93417 C09 t1997 NADH-dependent HCP oxidoreductase 1006 NP_805760.2 1.815109 93221 C10 t2370 acetyl esterase 1006 NP_806101.1 1.729622 93395 C11 t2455 preprotein translocase subunit SecF 1006 NP_806185.1 2.131213 93198 C12 t3222 octaprenyl diphosphate synthase 1006 NP_806898.1 1.9334 93217 D01 t3972 hypothetical protein t3972 1006 NP_807582.1 1.617296 93281 D02 t0275 signal peptidase I 1009 NP_804151.1 1.855302 93425 D03 t0332 cytoskeletal protein RodZ 1009 NP_804206.1 1.55996 93321 D04 t0779 CDP-6-deoxy-delta-3,4-glucoseen reductase 1009 NP_804621.1 1.791873 93265 D05 t1626 transcriptional regulator CysB 1009 NP_805404.1 1.690783 BEI Resources E-mail: [email protected] www.beiresources.org Tel: 800-359-7370 Fax: 703-365-2898 © 2014/2019 American Type Culture Collection (ATCC). All rights reserved. NR-19546_04JAN2019 Page 2 of 3 Product Information Sheet for NR-19546 Average Clone Well ORF Accession Locus ID Description Depth of ID Position Length Number Coverage 93210 D06 t2442 oxidoreductase 1009 NP_806172.1 1.732408 93338 D07 t2492 delta-aminolevulinic acid dehydratase 1009 NP_806220.1 1.772052 93374 D08 t3873 2-hydroxyacid dehydrogenase 1009 NP_807491.1 1.81665 93369 D09 t1135 inner membrane transport protein 1012 NP_804947.1 1.755929 93437 D10 t2444 thiamine monophosphate kinase 1012
Load more

Recommended publications
  • Propranolol-Mediated Attenuation of MMP-9 Excretion in Infants with Hemangiomas
    Supplementary Online Content Thaivalappil S, Bauman N, Saieg A, Movius E, Brown KJ, Preciado D. Propranolol-mediated attenuation of MMP-9 excretion in infants with hemangiomas. JAMA Otolaryngol Head Neck Surg. doi:10.1001/jamaoto.2013.4773 eTable. List of All of the Proteins Identified by Proteomics This supplementary material has been provided by the authors to give readers additional information about their work. © 2013 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 10/01/2021 eTable. List of All of the Proteins Identified by Proteomics Protein Name Prop 12 mo/4 Pred 12 mo/4 Δ Prop to Pred mo mo Myeloperoxidase OS=Homo sapiens GN=MPO 26.00 143.00 ‐117.00 Lactotransferrin OS=Homo sapiens GN=LTF 114.00 205.50 ‐91.50 Matrix metalloproteinase‐9 OS=Homo sapiens GN=MMP9 5.00 36.00 ‐31.00 Neutrophil elastase OS=Homo sapiens GN=ELANE 24.00 48.00 ‐24.00 Bleomycin hydrolase OS=Homo sapiens GN=BLMH 3.00 25.00 ‐22.00 CAP7_HUMAN Azurocidin OS=Homo sapiens GN=AZU1 PE=1 SV=3 4.00 26.00 ‐22.00 S10A8_HUMAN Protein S100‐A8 OS=Homo sapiens GN=S100A8 PE=1 14.67 30.50 ‐15.83 SV=1 IL1F9_HUMAN Interleukin‐1 family member 9 OS=Homo sapiens 1.00 15.00 ‐14.00 GN=IL1F9 PE=1 SV=1 MUC5B_HUMAN Mucin‐5B OS=Homo sapiens GN=MUC5B PE=1 SV=3 2.00 14.00 ‐12.00 MUC4_HUMAN Mucin‐4 OS=Homo sapiens GN=MUC4 PE=1 SV=3 1.00 12.00 ‐11.00 HRG_HUMAN Histidine‐rich glycoprotein OS=Homo sapiens GN=HRG 1.00 12.00 ‐11.00 PE=1 SV=1 TKT_HUMAN Transketolase OS=Homo sapiens GN=TKT PE=1 SV=3 17.00 28.00 ‐11.00 CATG_HUMAN Cathepsin G OS=Homo
    [Show full text]
  • Pseudouridine Synthase 1: a Site-Specific Synthase Without Strict Sequence Recognition Requirements Bryan S
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by PubMed Central Published online 18 November 2011 Nucleic Acids Research, 2012, Vol. 40, No. 5 2107–2118 doi:10.1093/nar/gkr1017 Pseudouridine synthase 1: a site-specific synthase without strict sequence recognition requirements Bryan S. Sibert and Jeffrey R. Patton* Department of Pathology, Microbiology and Immunology, University of South Carolina, School of Medicine, Columbia, SC 29208 USA Received May 20, 2011; Revised October 19, 2011; Accepted October 22, 2011 ABSTRACT rRNA and snRNA and requires Dyskerin or its homologs Pseudouridine synthase 1 (Pus1p) is an unusual (Cbf5p in yeast for example) and RNP cofactors [most site-specific modification enzyme in that it can often H/ACA small nucleolar ribonucleoprotein particles modify a number of positions in tRNAs and can rec- (snoRNPs)] that enable one enzyme to recognize many ognize several other types of RNA. No consensus different sites for modification on different substrates recognition sequence or structure has been identi- (17–25). The other pathway for É formation employs fied for Pus1p. Human Pus1p was used to determine site-specific É synthases that require no cofactors to rec- which structural or sequence elements of human ognize and modify the RNA substrate. A number of en- tRNASer are necessary for pseudouridine ()) forma- zymes have been identified in this pathway and are grouped in six families that all share a common basic tion at position 28 in the anticodon stem-loop (ASL). Ser structure (4). It is safe to say the cofactor ‘guided’ pathway Some point mutations in the ASL stem of tRNA has received a great deal of attention because of its simi- had significant effects on the levels of modification larity to aspects of RNA editing, but the site-specific and compensatory mutation, to reform the base pseudouridine synthases accomplish the same task, on pair, restored a wild-type level of ) formation.
    [Show full text]
  • TITLE PAGE Oxidative Stress and Response to Thymidylate Synthase
    Downloaded from molpharm.aspetjournals.org at ASPET Journals on October 2, 2021 -Targeted -Targeted 1 , University of of , University SC K.W.B., South Columbia, (U.O., Carolina, This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted.
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Appendix 3 and 4
    Appendix 3 : Conserved proteins present in L. interrogans serovar Canicola L. interrogans serovar Canicola Accession Number Protein identification Protein Length (Amino Acids) Mean No. of peptides Mean % Coverage 5,10 methylene tetrahydrofolate 45655587 310 7.67 11.33 reductase 45655588 274 hypothetical protein LIC20005 4.33 20.00 45655592 547 porphobilinogen deaminase 4.33 7.67 delta-aminolevulinic acid 45655593 317 15.00 20.33 dehydratase glutamate-1-semialdehyde 45655594 443 24.00 24.33 aminotransferase 45655597 340 uroporphyrinogen decarboxylase 2.67 5.67 45655598 443 coproporphyrinogen III oxidase 5.00 12.33 45655605 200 azoreductase 5.33 18.00 45655609 251 short-chain dehydrogenase 2.33 14.33 45655611 422 NADH dehydrogenase 3.67 11.00 45655613 202 hypothetical protein LIC20030 2.33 15.67 45655615 140 hypothetical protein LIC20032 4.33 15.67 45655617 356 hypothetical protein LIC20034 2.33 8.33 45655618 440 hypothetical protein LIC20035 8.17 14.67 methanol dehydrogenase 45655620 357 7.83 19.17 regulator 45655627 607 heat shock protein 90 9.33 14.83 45655628 189 hypothetical protein LIC20045 2.33 8.33 45655641 670 methylmalonyl-CoA mutase 14.33 14.33 phosphoribosyl-ATP 45655645 92 10.67 13.00 pyrophosphatase 3-oxoacyl-(acyl-carrier protein) 45655647 254 4.00 17.00 reductase 45655648 77 acyl carrier protein 3.67 9.00 45655661 171 hypothetical protein LIC20078 5.00 26.00 4-hydroxybenzoyl-CoA 45655663 142 3.33 11.67 thioesterase S-adenosyl-L-homocysteine 45655666 436 13.00 19.67 hydrolase B12-dependent methionine 45655668 1247 42.67 21.67
    [Show full text]
  • Figure S1. HAEC ROS Production and ML090 NOX5-Inhibition
    Figure S1. HAEC ROS production and ML090 NOX5-inhibition. (a) Extracellular H2O2 production in HAEC treated with ML090 at different concentrations and 24 h after being infected with GFP and NOX5-β adenoviruses (MOI 100). **p< 0.01, and ****p< 0.0001 vs control NOX5-β-infected cells (ML090, 0 nM). Results expressed as mean ± SEM. Fold increase vs GFP-infected cells with 0 nM of ML090. n= 6. (b) NOX5-β overexpression and DHE oxidation in HAEC. Representative images from three experiments are shown. Intracellular superoxide anion production of HAEC 24 h after infection with GFP and NOX5-β adenoviruses at different MOIs treated or not with ML090 (10 nM). MOI: Multiplicity of infection. Figure S2. Ontology analysis of HAEC infected with NOX5-β. Ontology analysis shows that the response to unfolded protein is the most relevant. Figure S3. UPR mRNA expression in heart of infarcted transgenic mice. n= 12-13. Results expressed as mean ± SEM. Table S1: Altered gene expression due to NOX5-β expression at 12 h (bold, highlighted in yellow). N12hvsG12h N18hvsG18h N24hvsG24h GeneName GeneDescription TranscriptID logFC p-value logFC p-value logFC p-value family with sequence similarity NM_052966 1.45 1.20E-17 2.44 3.27E-19 2.96 6.24E-21 FAM129A 129. member A DnaJ (Hsp40) homolog. NM_001130182 2.19 9.83E-20 2.94 2.90E-19 3.01 1.68E-19 DNAJA4 subfamily A. member 4 phorbol-12-myristate-13-acetate- NM_021127 0.93 1.84E-12 2.41 1.32E-17 2.69 1.43E-18 PMAIP1 induced protein 1 E2F7 E2F transcription factor 7 NM_203394 0.71 8.35E-11 2.20 2.21E-17 2.48 1.84E-18 DnaJ (Hsp40) homolog.
    [Show full text]
  • Taqman Probes ARF 5' Primer P16ink4a 5' Primer Exon 1/2
    a b Exon 1β 1α 23 ARF p16INK4a MDM2 Cyclin D CDK4/6 p53 pRB TaqMan Probes ARF 5’ Primer p16INK4a 5’ Primer Exon 1/2 Common Primer Exon 2/3 Common Primers Defective p53 Intact p53 A. Melanoma cell lines clustered by expression of p53 targets and INK4a/ARF expression. The p53 response to ionizing radiation is indicated. Top cluster: Cells with intact p53 response show increased expression of the eight indicated p53 targets, and decreased expression of ARF. Bottom cluster: TaqMan and microarray results for the p16INK4- and ARF- specific transcripts. Cell lines that demonstrated increased p16INK4a expression either harbored RB deletion, p16INK4a point 2 mutation or CDK4 point mutation (Supp Table 1). Pair-wise variances (r ) for the log2 transformed CDKN2a microarray 2 2 2 results versus the log10 transformed TaqMan results are: vs. Exon 2/3 r =0.78; vs. Exon1α/2 r =0.32; vs. Exon 1β/2 r =0.38. Note all four WT lines (PMWK, Mel505, SKMEL187 and RPMI8322) lack evidence of p53 function by all assays. B. The INK4a/ARF locus and with TaqMan strategies. The ARF transcript originates from exon 1β while the p16INK4a transcript originates from exon 1α. Both transcripts splice to exon 2 but in alternate reading frames. ARF stabilizes p53 by inhibiting MDM2, while p16INK4a activates RB by inhibiting CDK4. Primers and TaqMan probes are shown for the real-time RT-PCR strategy. Shields et al., Supp Figure 1 SKMEL 28 U01 24h SKMEL WM2664 U01 48h WM2664 U01 24h 24 U01 48h SKMEL 24 U01 24h SKMEL 24 Untreated SKMEL 24 DMSO 48h SKMEL 24 DMSO 24h SKMEL WM2664 DMSO 24h WM2664 DMSO 48h WM2644 Untreated 28 Untreated SKMEL 28 DMSO 48h SKMEL 28 DMSO 24h SKMEL -3.00 -2.00 -1.00 0.00 1.00 2.00 3.00 relative to median expression Genes decreased by UO1 (863) HIF1A Hypoxia-inducible factor 1, alpha subunit NM_001530 RBBP8 Retinoblastoma binding protein 8 NM_002894 Homo sapiens, clone IMAGE:4337652, mRNA BC018676 EIF4EBP1 Eukaryotic translation initiation factor 4E binding protein EXOSC8 Exosome component 8 NM_181503 ENST00000321524 MCM7 MCM7 minichromosome maintenance deficient 7 (S.
    [Show full text]
  • Q 297 Suppl USE
    The following supplement accompanies the article Atlantic salmon raised with diets low in long-chain polyunsaturated n-3 fatty acids in freshwater have a Mycoplasma dominated gut microbiota at sea Yang Jin, Inga Leena Angell, Simen Rød Sandve, Lars Gustav Snipen, Yngvar Olsen, Knut Rudi* *Corresponding author: [email protected] Aquaculture Environment Interactions 11: 31–39 (2019) Table S1. Composition of high- and low LC-PUFA diets. Stage Fresh water Sea water Feed type High LC-PUFA Low LC-PUFA Fish oil Initial fish weight (g) 0.2 0.4 1 5 15 30 50 0.2 0.4 1 5 15 30 50 80 200 Feed size (mm) 0.6 0.9 1.3 1.7 2.2 2.8 3.5 0.6 0.9 1.3 1.7 2.2 2.8 3.5 3.5 4.9 North Atlantic fishmeal (%) 41 40 40 40 40 30 30 41 40 40 40 40 30 30 35 25 Plant meals (%) 46 45 45 42 40 49 48 46 45 45 42 40 49 48 39 46 Additives (%) 3.3 3.2 3.2 3.5 3.3 3.4 3.9 3.3 3.2 3.2 3.5 3.3 3.4 3.9 2.6 3.3 North Atlantic fish oil (%) 9.9 12 12 15 16 17 18 0 0 0 0 0 1.2 1.2 23 26 Linseed oil (%) 0 0 0 0 0 0 0 6.8 8.1 8.1 9.7 11 10 11 0 0 Palm oil (%) 0 0 0 0 0 0 0 3.2 3.8 3.8 5.4 5.9 5.8 5.9 0 0 Protein (%) 56 55 55 51 49 47 47 56 55 55 51 49 47 47 44 41 Fat (%) 16 18 18 21 22 22 22 16 18 18 21 22 22 22 28 31 EPA+DHA (% diet) 2.2 2.4 2.4 2.9 3.1 3.1 3.1 0.7 0.7 0.7 0.7 0.7 0.7 0.7 4 4.2 Table S2.
    [Show full text]
  • Supplementary Informations SI2. Supplementary Table 1
    Supplementary Informations SI2. Supplementary Table 1. M9, soil, and rhizosphere media composition. LB in Compound Name Exchange Reaction LB in soil LBin M9 rhizosphere H2O EX_cpd00001_e0 -15 -15 -10 O2 EX_cpd00007_e0 -15 -15 -10 Phosphate EX_cpd00009_e0 -15 -15 -10 CO2 EX_cpd00011_e0 -15 -15 0 Ammonia EX_cpd00013_e0 -7.5 -7.5 -10 L-glutamate EX_cpd00023_e0 0 -0.0283302 0 D-glucose EX_cpd00027_e0 -0.61972444 -0.04098397 0 Mn2 EX_cpd00030_e0 -15 -15 -10 Glycine EX_cpd00033_e0 -0.0068175 -0.00693094 0 Zn2 EX_cpd00034_e0 -15 -15 -10 L-alanine EX_cpd00035_e0 -0.02780553 -0.00823049 0 Succinate EX_cpd00036_e0 -0.0056245 -0.12240603 0 L-lysine EX_cpd00039_e0 0 -10 0 L-aspartate EX_cpd00041_e0 0 -0.03205557 0 Sulfate EX_cpd00048_e0 -15 -15 -10 L-arginine EX_cpd00051_e0 -0.0068175 -0.00948672 0 L-serine EX_cpd00054_e0 0 -0.01004986 0 Cu2+ EX_cpd00058_e0 -15 -15 -10 Ca2+ EX_cpd00063_e0 -15 -100 -10 L-ornithine EX_cpd00064_e0 -0.0068175 -0.00831712 0 H+ EX_cpd00067_e0 -15 -15 -10 L-tyrosine EX_cpd00069_e0 -0.0068175 -0.00233919 0 Sucrose EX_cpd00076_e0 0 -0.02049199 0 L-cysteine EX_cpd00084_e0 -0.0068175 0 0 Cl- EX_cpd00099_e0 -15 -15 -10 Glycerol EX_cpd00100_e0 0 0 -10 Biotin EX_cpd00104_e0 -15 -15 0 D-ribose EX_cpd00105_e0 -0.01862144 0 0 L-leucine EX_cpd00107_e0 -0.03596182 -0.00303228 0 D-galactose EX_cpd00108_e0 -0.25290619 -0.18317325 0 L-histidine EX_cpd00119_e0 -0.0068175 -0.00506825 0 L-proline EX_cpd00129_e0 -0.01102953 0 0 L-malate EX_cpd00130_e0 -0.03649016 -0.79413596 0 D-mannose EX_cpd00138_e0 -0.2540567 -0.05436649 0 Co2 EX_cpd00149_e0
    [Show full text]
  • MMP-25 Metalloprotease Regulates Innate Immune Response Through NF- Κb Signaling Clara Soria-Valles, Ana Gutiérrez-Fernández, Fernando G
    MMP-25 Metalloprotease Regulates Innate Immune Response through NF- κB Signaling Clara Soria-Valles, Ana Gutiérrez-Fernández, Fernando G. Osorio, Dido Carrero, Adolfo A. Ferrando, Enrique Colado, This information is current as M. Soledad Fernández-García, Elena Bonzon-Kulichenko, of October 5, 2021. Jesús Vázquez, Antonio Fueyo and Carlos López-Otín J Immunol published online 3 June 2016 http://www.jimmunol.org/content/early/2016/06/01/jimmun ol.1600094 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2016/06/01/jimmunol.160009 Material 4.DCSupplemental http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on October 5, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2016 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Published June 3, 2016, doi:10.4049/jimmunol.1600094 The Journal of Immunology MMP-25 Metalloprotease Regulates Innate Immune Response through NF-kB Signaling Clara Soria-Valles,* Ana Gutie´rrez-Ferna´ndez,* Fernando G. Osorio,* Dido Carrero,* Adolfo A.
    [Show full text]
  • Supplemental Table S1: Comparison of the Deleted Genes in the Genome-Reduced Strains
    Supplemental Table S1: Comparison of the deleted genes in the genome-reduced strains Legend 1 Locus tag according to the reference genome sequence of B. subtilis 168 (NC_000964) Genes highlighted in blue have been deleted from the respective strains Genes highlighted in green have been inserted into the indicated strain, they are present in all following strains Regions highlighted in red could not be deleted as a unit Regions highlighted in orange were not deleted in the genome-reduced strains since their deletion resulted in severe growth defects Gene BSU_number 1 Function ∆6 IIG-Bs27-47-24 PG10 PS38 dnaA BSU00010 replication initiation protein dnaN BSU00020 DNA polymerase III (beta subunit), beta clamp yaaA BSU00030 unknown recF BSU00040 repair, recombination remB BSU00050 involved in the activation of biofilm matrix biosynthetic operons gyrB BSU00060 DNA-Gyrase (subunit B) gyrA BSU00070 DNA-Gyrase (subunit A) rrnO-16S- trnO-Ala- trnO-Ile- rrnO-23S- rrnO-5S yaaC BSU00080 unknown guaB BSU00090 IMP dehydrogenase dacA BSU00100 penicillin-binding protein 5*, D-alanyl-D-alanine carboxypeptidase pdxS BSU00110 pyridoxal-5'-phosphate synthase (synthase domain) pdxT BSU00120 pyridoxal-5'-phosphate synthase (glutaminase domain) serS BSU00130 seryl-tRNA-synthetase trnSL-Ser1 dck BSU00140 deoxyadenosin/deoxycytidine kinase dgk BSU00150 deoxyguanosine kinase yaaH BSU00160 general stress protein, survival of ethanol stress, SafA-dependent spore coat yaaI BSU00170 general stress protein, similar to isochorismatase yaaJ BSU00180 tRNA specific adenosine
    [Show full text]
  • 12) United States Patent (10
    US007635572B2 (12) UnitedO States Patent (10) Patent No.: US 7,635,572 B2 Zhou et al. (45) Date of Patent: Dec. 22, 2009 (54) METHODS FOR CONDUCTING ASSAYS FOR 5,506,121 A 4/1996 Skerra et al. ENZYME ACTIVITY ON PROTEIN 5,510,270 A 4/1996 Fodor et al. MICROARRAYS 5,512,492 A 4/1996 Herron et al. 5,516,635 A 5/1996 Ekins et al. (75) Inventors: Fang X. Zhou, New Haven, CT (US); 5,532,128 A 7/1996 Eggers Barry Schweitzer, Cheshire, CT (US) 5,538,897 A 7/1996 Yates, III et al. s s 5,541,070 A 7/1996 Kauvar (73) Assignee: Life Technologies Corporation, .. S.E. al Carlsbad, CA (US) 5,585,069 A 12/1996 Zanzucchi et al. 5,585,639 A 12/1996 Dorsel et al. (*) Notice: Subject to any disclaimer, the term of this 5,593,838 A 1/1997 Zanzucchi et al. patent is extended or adjusted under 35 5,605,662 A 2f1997 Heller et al. U.S.C. 154(b) by 0 days. 5,620,850 A 4/1997 Bamdad et al. 5,624,711 A 4/1997 Sundberg et al. (21) Appl. No.: 10/865,431 5,627,369 A 5/1997 Vestal et al. 5,629,213 A 5/1997 Kornguth et al. (22) Filed: Jun. 9, 2004 (Continued) (65) Prior Publication Data FOREIGN PATENT DOCUMENTS US 2005/O118665 A1 Jun. 2, 2005 EP 596421 10, 1993 EP 0619321 12/1994 (51) Int. Cl. EP O664452 7, 1995 CI2O 1/50 (2006.01) EP O818467 1, 1998 (52) U.S.
    [Show full text]